Tag
NASDAQ: IBB
- Merck says remigromig met BRUNELLO vision endpoint, flags eye risks
- Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss
- Scancell signs up to US$25M debt facility for melanoma Phase 3
- Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote
- Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
- Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint